Question 5
Herealshi
LEARNINGRESOURCE1forwk5NR.docxLEARNING RESOURCES
https://www.ahrq.gov/sites/default/files/publications/files/pemat_guide.pdf
Thapar, A., Pine, D. S., Leckman, J. F., Scott, S., Snowling, M. J., & Taylor, E. A. (2015). Rutter’s child and adolescent psychiatry (6th ed.). Wiley Blackwell.
· Chapter 60, “Anxiety Disorders”
· Chapter 61, “Obsessive Compulsive Disorder”
· Chapter 62, “Bipolar Disorder in Childhood”
· Chapter 63, “Depressive Disorders in Childhood and Adolescence”
REQUIRED MEDIA
https://www.youtube.com/watch?v=Wn4AVjMMYX4
Medication Review
Review the FDA-approved use of the following medicines related to treating mood and anxiety disorders in children and adolescents.
|
Bipolar depression |
Bipolar disorder |
|
lurasidone (age 10–17) olanzapine-fluoxetine combination (age 10–17) |
aripiprazole (age 10–17) asenapine (for mania or mixed episodes, age 10–17) lithium (for mania, age 12–17) olanzapine (age 13–17) quetiapine (age 10–17) risperidone (age 10–17) |
|
Generalized anxiety disorder |
Depression |
|
duloxetine (age 7–17) |
escitalopram (age 12–17) fluoxetine (age 8–17) |
|
Obsessive-compulsive disorder |
|
clomipramine (age 10–17) fluoxetine (age 7–17) fluvoxamine (age 8–17) sertraline (age 6–17) |
LEARNI
NG RESOURCES
https://ezp.waldenulibrary.org/login?url=https://search.ebscohost.com/login.aspx?direct=true&db=cat
06423a&AN=wal.EBC5108631&site=eds
-
live&scope=site
https://www.ahrq
.gov/sites/default/files/publications/files/pemat_guide.pdf
Thapa
r, A., Pine, D. S.,
Leckman, J. F., Scott, S.,
Snowling, M. J., & Taylor, E. A. (2015).
Rutter’s child and
adolescent psychiatry
(6th ed.). Wiley Blackwell.
·
Chapter 60, “Anxiety Disorders”
·
Chapter 61, “Obsessive Compulsive Disorder”
·
Chapter 62, “Bipolar Di
sorder in Childhood”
·
Chapter 63, “Depressive Disorders in Childhood and Adolescence”
REQUIRED MEDIA
https://youtu.be/tSfYXkst1vM
https://youtu.be/Qg
-
BBKB1nJc
https://www.you
tube.com/watch?v=Wn4AVjMMYX4
Medication Review
Review the FDA
-
approved use of the following medicines related to treating mood and anxiety disorders
in children and adolescents.
Bipolar depression
Bipolar disorder
lurasidone (age 10
–
17)
olanzapine
-
fluoxetine combination (age 10
–
17)
aripiprazole (age 10
–
17)
asenapine
(for mania or mixed episodes,
LEARNING RESOURCES
https://ezp.waldenulibrary.org/login?url=https://search.ebscohost.com/login.aspx?direct=true&db=cat
06423a&AN=wal.EBC5108631&site=eds-live&scope=site
https://www.ahrq.gov/sites/default/files/publications/files/pemat_guide.pdf
Thapar, A., Pine, D. S., Leckman, J. F., Scott, S., Snowling, M. J., & Taylor, E. A. (2015). Rutter’s child and
adolescent psychiatry (6th ed.). Wiley Blackwell.
Chapter 60, “Anxiety Disorders”
Chapter 61, “Obsessive Compulsive Disorder”
Chapter 62, “Bipolar Disorder in Childhood”
Chapter 63, “Depressive Disorders in Childhood and Adolescence”
REQUIRED MEDIA
https://youtu.be/tSfYXkst1vM
https://youtu.be/Qg-BBKB1nJc
https://www.youtube.com/watch?v=Wn4AVjMMYX4
Medication Review
Review the FDA-approved use of the following medicines related to treating mood and anxiety disorders
in children and adolescents.
Bipolar depression Bipolar disorder
lurasidone (age 10–17)
olanzapine-fluoxetine combination (age 10–17)
aripiprazole (age 10–17)
asenapine (for mania or mixed episodes,
